Tobacco induced diseases · 2026
Delivery of a one-week chewing gum for promoting smoking cessation: A pilot randomized controlled trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Meng Yao, Yiu Yin Ting, Zhao Sheng Zhi, Cheung Yee Tak Derek, Deng Ke, Lam Tai Hing, Wang Man Ping
Аннотация
INTRODUCTION: Chewing gum has been used as a self-help strategy for managing smoking cravings, yet its effectiveness has not been evaluated. This pilot trial assessed the feasibility, acceptability, and preliminary effectiveness of delivering 1-week chewing gum for promoting quitting.
METHODS: Adult daily smokers were recruited from smoking hotspots in Hong Kong in February 2025. All participants received very brief advice (VBA) and a selfhelp booklet at baseline. The intervention group additionally received 1 week of chewing gum (2 packs) and 2 weeks of instant messaging reminders to promote gum usage, whereas the control group received no placebo or sham intervention beyond VBA and the booklet. Follow-up was conducted at 2 weeks, 3 months, and 6 months post-enrolment. The primary outcome was biochemically validated tobacco abstinence at 6 months. Risk ratios (RRs) were used to estimate the intervention effect using intention-to-treat analysis in Poisson regression.
RESULTS: The recruitment rate was 91%, and the retention rate was 86%, 78%, and 74% at 2 weeks, 3 months, and 6 months, respectively. Eighty participants were randomly assigned to the intervention (n=40) and control (n=40) groups using a 1:1 allocation ratio. The intervention group had a higher validated abstinence (10% vs 0%; risk difference, RD=0.53; 95% CI: 0.41-0.64) at 6 months than the control group. Among intervention group participants, 75% (30/40) used chewing gum, and 57% (17/30) rated it as helpful in relieving cravings. Those who used the chewing gum had higher rates of quit attempts (77% vs 40%, p=0.03) and smoking reduction (73% vs 40%, p=0.06) than those who did not.
CONCLUSIONS: Delivering chewing gum was feasible and showed preliminary evidence of effectiveness in cessation outcomes. Full trials with an extended intervention period are warranted.
CLINICAL TRIAL REGISTRATION: The study is registered on the official website of ClinicalTrials.gov.
IDENTIFIER: CT06801860.
METHODS: Adult daily smokers were recruited from smoking hotspots in Hong Kong in February 2025. All participants received very brief advice (VBA) and a selfhelp booklet at baseline. The intervention group additionally received 1 week of chewing gum (2 packs) and 2 weeks of instant messaging reminders to promote gum usage, whereas the control group received no placebo or sham intervention beyond VBA and the booklet. Follow-up was conducted at 2 weeks, 3 months, and 6 months post-enrolment. The primary outcome was biochemically validated tobacco abstinence at 6 months. Risk ratios (RRs) were used to estimate the intervention effect using intention-to-treat analysis in Poisson regression.
RESULTS: The recruitment rate was 91%, and the retention rate was 86%, 78%, and 74% at 2 weeks, 3 months, and 6 months, respectively. Eighty participants were randomly assigned to the intervention (n=40) and control (n=40) groups using a 1:1 allocation ratio. The intervention group had a higher validated abstinence (10% vs 0%; risk difference, RD=0.53; 95% CI: 0.41-0.64) at 6 months than the control group. Among intervention group participants, 75% (30/40) used chewing gum, and 57% (17/30) rated it as helpful in relieving cravings. Those who used the chewing gum had higher rates of quit attempts (77% vs 40%, p=0.03) and smoking reduction (73% vs 40%, p=0.06) than those who did not.
CONCLUSIONS: Delivering chewing gum was feasible and showed preliminary evidence of effectiveness in cessation outcomes. Full trials with an extended intervention period are warranted.
CLINICAL TRIAL REGISTRATION: The study is registered on the official website of ClinicalTrials.gov.
IDENTIFIER: CT06801860.